Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma

    loading  Checking for direct PDF access through Ovid

Abstract

The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1− cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 ± 10−4; 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 ± 10−4 and 2 ± 10−3, respectively) and a negative one for MIB 1 cells (P = 2 ± 10−3). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3−). Sclerosis might be Interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1- cells) as the conseqence of cytolytic action.

Related Topics

    loading  Loading Related Articles